Cervical cancer (CC) is the fourth leading cause of cancer among women worldwide
In recent years the development of new analytical techniques in DNA sequencing and biomolecule measurements has expanded the ability to characterize phenotypic changes in pathological processes
Given the current scenario in which CC continues to be a serious health problem for women, metabolomics can be a useful tool in expanding the knowledge on this disease. This review aims to systematically analyze metabolomic approaches in the study of cervical cancer, describing the specific metabolites associated with the development of cervical cancer, identifying possible biomarkers and metabolomic profiles in the context of cervical neoplasia which can lead to innovative clinical approaches.
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
A computerized bibliographic search was carried out in the electronic databases MEDLINE / PubMed, Latin American and Caribbean Literature in Health Sciences (LILACS), Scientific Electronic Library Online (SciELO), Virtual Health Library (VHL) and the databases of gray literature: Google Scholar and Open Gray. As descriptors, the terms in force in the Medical Subject Headings (MeSH) and Health Sciences Descriptors (DeCS) corresponding to “Metabolomics” and “Cervical Cancer” were used. The terms were combined with the Boolean operators “AND” and “OR” (Appendix S1). A manual search was also carried out on the reference list of the selected articles. All searches were carried out from 08/28/2020 to 05/11/2021.
The works were identified by title and abstract by two reviewers (N.D.A. and A.J.S.), who followed the inclusion and exclusion criteria. Studies without abstracts whose title suggested meeting the selection criteria were also selected for analysis. All divergences were resolved by consulting a third reviewer (M.A.M.), who finally defined which articles would be fully read. The selected works were read in full by three authors. Then, the studies were included in the systematic review upon agreement of the three reviewers.
Observational studies that included the use of metabolomics, obtained through biological samples, from patients diagnosed with CC were included in the search. Articles describing the metabolic profiles of tissues and samples and the potential use of metabolomics as a diagnostic and prognostic tool were included. There was no limitation on time or publication language. Studies whose interventions involved specific analysis on drug therapy, carried out on animals, case reports, letters, abstracts, conference proceedings, case studies, review or conglomerates were excluded.
The information extracted from studies included: author, date of publication, geographic origin, title, magazine, type of study, financing, among others. Data on the participants of each work, number of participants, sex, age, use of medications and comorbidities were recorded. The patients in the selected studies were divided into three groups: patients with cervical cancer, patients with intraepithelial lesions and the control group constituted by healthy women (not every selected article described all three categories). Finally, data from metabolomic analysis were collected, such as the method used, the analyzed sample (fluid or biological tissue) and the metabolites found in association with cancer.
Article quality was accessed using QUADOMICS
A total of 124 references were identified in the initial search. 24 articles were selected for complete reading. Seven studies were further excluded for the following reasons: two for containing analysis exclusive for HPV, two for treating only high-grade intraepithelial lesions, two for using metabolomics for specific analysis and one due to the impossibility of separating the results from cervical cancer patients from other patients. Finally, 17 articles
All studies selected for systematic review were published in the English language, from 2004 to 2021 (
| Author, year | Origin | N (patients) | Age (average years old) | Sample type | Platform Analytics | ||
|---|---|---|---|---|---|---|---|
| CC | CIN | Control | |||||
| Abdula et al. 2020 | China | 21 | 20 CIN II/III | 11 | 45.2 | Cervical tissue | HRMAS 1H NMR |
| Rodrígues-Esquivel et al. 2018 | Mexico | 15 | - | 15 | Women over 20 years old | Volatile organic components | GC/MS |
| Ilhan et al. 2019 | USA | 10 | 12 LSIL 27 HSIL | 29 | 38+8 | Cervical washes | UPLC/MS |
| Khan et al. 2019 | Korea | 60 | 55 CIN I 42 CIN II/III | 69 | CC: 50 / Control: 48 / CIN I: 35 / CIN II / III: 39.5 | Plasma | UPLC-QTOF/MS |
| Paraskevaidi et al. 2020 | England | 5 | 30 CIN I 40 CIN II/III | 49 | CC: 47.6 / Control: 35.1 CIN I: 35 34.9 / CIN II: 35.3/CIN III:34.2 | Cervical cells | LA-REIMS |
| Yang et al. 2017 | China | 66 | - | 69 | CC: 49.84 / Control: 54 | Plasma | UPLC-QTOF/MS |
| Ye et al. 2015 | China | 18 30 AT | 9 | - | CC: 40/CIN: 33 | Serum | 1H NMR |
| Zhou et al. 2019 | China | 30 PR 30 PB | - | - | BT: 52.20 / PP: 53.27 / GP: 52.40 | Plasma | UPLC-QTOF/MS |
| De Silva et al. 2009 | England | 23 | 5 CIN I 40 CIN II/III | 5 | CC + CIN: 37/Control: 52 | Cervical tissue | HRMAS 1H NMR |
| Hasim et al. 2012 | China | 38 | 2 CIN I 36 CIN II/III | 38 | CC:45.6±0.3 / Control: 41.6 ± 0.3 / CIN: 39.6 ± 0.7 | Plasma | 1HNMR |
| Hasim et al. 2013 | China | 22 | 10 CIN II 16 CIN III | 35 | CC: 52.7/CIN: 46.3 | Plasma | HPLC-MS |
| Shi et al. 2015 | China | 5 | - | 6 | CC: 35-43 Control: 25-28 | Serum | GC-MS |
| Sitter et al. 2004 | Norway | 8 | - | 8 | 50 | Cervical tissue | HRMAS 1H NMR |
| Yin et al. 2015 | China | 89 | - | 93 | CC: 46.39±9.56 Control: 47.55 ±7.07 | Plasma | UPLC-MS |
| Chen et al. 2021 | China | 21 | 13 LSIL 22 HSIL | 24 | - | Cervical tissue | GC-MS |
| Nan et al. 2021 | Korea | 60 | 55 CIN I 44 CIN II/III | 66 | CC: 50/CIN I: 35 /CIN II/III: 39.5 Control: 48 | Plasma | UPLC-QTOF-MS |
| Cheng et al. 2020 | China | 25 | 27 CIN | 20 | CC: 48.48 ± 2.29 / CIN: 46.67 ± 1.64 / Control: 47.30 ± 2.71 | Serum | UHPLC-QTOF/MS |
Caption: 1H NMR = Proton nuclear magnetic resonance. HRMAS 1H NMR = High resolution magic angle rotating nuclear magnetic resonance. GC-MS = Gas chromatography coupled to mass spectrometry. UPLC-MS = Ultra-efficient liquid chromatography coupled with mass spectrometry. UPLC-QTOF / MS = Ultra high-performance liquid chromatography quadrupole time-of-flight mass spectrometry. LA-REIMS = Laser ablation coupled with rapid evaporative mass spectrometry. MALDI-TOF / MS = Matrix-assisted laser ionization and desorption coupled with mass spectrometry. CC = Cervical cancer. CIN = cervical intraepithelial neoplasia. Control= Healthy woman. LSIL= Low-grade intraepithelial lesion. HSIL = High-grade intraepithelial lesion. - = not reported.
The average age of patients with CC in the investigated articles ranged between 40 and 50 years. All 576 patients with CC were diagnosed through the association of clinical analysis and histological exams and a total of 529 patients made up the control group. Five articles presented HPV testing and of the 156 cervical cancer patients tested 129 (82.7%) were HPV +. Women with intraepithelial lesions totaled 505, 182 with LSIL (NIC I), 287 with HSIL (NIC II / III) and for 36 patients the lesion degree was not described.
Sample types used for metabolomic analysis included blood serum/plasma (10), cervical tissue (4), cervical cells (1), volatile organic components (VOCs; 1) and cervical washes (1). Metabolomics studies were conducted using NMR (five articles), liquid chromatography coupled to mass spectrometry (LC-MS; eight articles), gas chromatography coupled to mass spectrometry (GC-MS; three articles) and laser ablation coupled to rapid evaporative mass spectrometry (LA-REIMS; 1 article) (
Within the 17 selected studies, 16 reported some type of support or funding. Only Sitter et al. (2004) did not report any financial support.
From the 17 items recommended by QUADOMICS two were not used (items 2 and 14) since these are applicable to phase IV clinical studies which were not present in our sampled articles. Six articles reached 80% or more of the evaluated QUADOMICS criteria (12/15). Among these, Paraskevaidi et al. (2020) and Ying et al. (2015) obtained the highest score, reaching the proposed quality criteria for 13 items (87%;
75 metabolite alterations were mentioned as relevant in the context of cervical cancer (
| Reference | Altered metabolites in the CC | P value | Sensitivity | Specificity | AUC | Conclusion |
|---|---|---|---|---|---|---|
| Khan et al. 2019 | CC × Control and CC × CIN: AMP, aspartate, glutamate, hypoxanthine, lactate, proline, pyroglutamate. | <0.01 | - | - | CC × Control: 0.83* / CC X CIN: 0.78* | High level of the referred metabolites presents a greater risk of developing cervical dysplasia (OR 2.94-4.48). |
| Yang et al. 2017 | CC × Control: Bilirubin, lysoPC (17: 0), n-oleoyl threonine, 12-hydroxydodecanoic acid and tetracosahexaenoic acid. | <0.05 | 0.98 | 0.99 | 0.99* | The combination of 5 biomarkers establishing a promising method for the diagnosis and screening of cervical cancer. |
| Ye et al. 2015 | CC × CIN: Alanine, glutamine, carnitine, inositol, β-glucose and formate. | <0.05 | - | - | - | These 6 metabolites can be identified as potential biomarkers and used to discriminate CC. |
| Zhou et al. 2019 | Phosphatidylcholine [PC (15: 0/16: 0)], phosphatidylglycerol [PG (12: 0/13: 0), lactosylceramide, D-Maltose and phthalic acid. | - | BT × PP:0.94 BT × GP:0.92 GP × PP:0.86 | BT × PP:0.87 BT × GP:0.89 GP × PP:0.80 | BT x PP: 0.97* BTxGP:0.97* GTvsPP:0.91* | Five metabolites were identified as potential biomarkers for prognosis of patients with CC. |
| Hasim et al. 2012 | CC × control: Acetate, format, creatine, lactate, isoleucine, leucine, valine, alanine, glutamine, histidine and tyrosine. / CC X CIN: Acetate, acetone, format, glycoprotein, α-glucose and β-glucose. | <0.05 | >0.90 | >0.95 | - | Differences in metabolomic signatures that can distinguish between CC, CIN and healthy controls. |
| Hasim et al. 2013 | CC × Control and CC X CIN: Arginine, threonine, aspartate, glutamate, asparagine, serine, glycine, histidine, taurine, tyrosine, valine, methionine, lysine, isoleucine, leucine and phenylalanine. | <0.04 | Plasma free amino acid profiles may have the potential to be used to diagnose cancer and improve the understanding of it's mechanisms. | |||
| Shi et al. 2015 | CC x Control: Ethanedioic acid, phosphate, guloCIN acid, ethoxypropionic acid, pyruvic acid, l-valine, propanoic acid, 2-ketoiso-caprylic acid, isotridecyl alcohol, adenosine, l-oroline, dimethylpyruvic acid and tridecanol. | <0.05 | - | - | - | The results suggested that metabolomics is capable of differentiating cervical cancer patients from healthy controls. |
| Yin et al. 2015 | CC x Control: PC (18: 2/20: 5), lysoPC (10: 0), lysoPC (18: 0) and PC (18:1 /15: 0) | - | 0.93 | 0.91 | 0.972* | Four candidate biomarkers for diagnostic purposes, which when combined have high sensitivity, specificity and AUC. |
| Nam et al. 2021 | CC X control: Acylcamitine, Diglyceride, LysoPE, PC, PE and free fatty acid./ CC X CIN: Acylcamitine, ceramide, triglyceride, diglyceride, LysoPE, PC and free fatty acid. | <0.05 | - | - | - | These results suggest that the lipid profile is a useful method for monitoring the progression to cervical cancer. |
| Cheng et al. 2020 | PC 14:0/18:2, PE 15:1 e/22:6, PE 16:1 e/18:2, and PE16:1e/20:5 | - | 0.920 | 0,915 | 0,961* | This panel was effective in distinguishing between CC and non-CC. |
| Abdula et al. 2020 | CC × CIN + Control: LDL, lactate, alanine, α-glucose, β-glucose, tyrosine and phenylalanine CC × Control: Creatine, acetate, scyllo-inositol, isoleucine and methylproline. | - | - | - | - | Reduction in the levels of α and β-glucose in CC and CIN group, increase in lactate and LDL and alteration in the expression of multiple amino acids in CC group compared with control group. |
| De Silva et al. 2009 | CC × Control: PE, phosphate, alanine, creatine CC × CIN: PC and choline. | <0.01 | - | - | - | PE and phosphate were increased, and alanine and creatine reduced in patients with CC compared to control. |
| Sitter et al. 2004 | CC × Control: Lactate, methyl and methylene groups of lipids, compounds containing choline, creatine, taurine, alanine and β-glucose. | - | - | - | - | Larger sample studies are needed to assess the clinical value of this method in the CC. |
| Chen et al. 2021 | CC × Control Glucose, lactate, glycine, aspartate, alanine, tyrosine, phosphate, pyrimidine and arachidonate. | <0.05 | - | - | - | The content of various amino acids, such as glycine, aspartate, alanine, tyrosine and serine, increased in CC. |
| Rodrígues-Esquivel et al. 2018 | CC × Control: Octane, 2,2,6-trimethyl-992 (alkane), decane, 2,6,10-trimethyl-1320 (alkane), octane, 2,2,6-trimethyl 1029 (alkane), undecane, 2,2- dimethyl-1828 (alkane), 2-methylpentyl 917 (Ester) and hexane, 2,2,4-trimethyl- (Alkane). | <0.05 | 0.93 | 0.93 | 0.86* | Specific VOCs are potential biomarkers and can function as a complementary tool for the diagnosis of the disease. |
| Ilhan et al. 2019 | CC × Control: 3-hydroxybutyrate, eicosenoate and oleate / vaccenate | - | - | - | >0.90** | Cervical dysplasia led to depletion of metabolites. These amino acid and nucleotide metabolites were able to distinguish the studied groups. |
| Paraskevaidi et al. 2021 | - | - | 0.91 | 0.73 | 0.867 (95% Cl 0.746-0.947) | LA-REIMS was able to classify 41 out of 45 patients with high-grade lesions and CC and 40 out of 55 healthy individuals. |
Legend: AUC = Area under the curve. CC = Cervical cancer. CIN = cervical intraepithelial neoplasia. BT = before treatment /GP = good prognosis /PP = poor prognosis. LDL = low density lipoproteins. PC = phosphatidylcholine. PE = phosphatidylethanolamine. LysoPC = lysophosphatidylcholine. LA-REIMS = Laser ablation coupled with rapid evaporative mass spectrometry. VOCs = Volatile organic compounds. / - = not reported. * = AUC results obtained by combining the altered metabolites, the values for each specific metabolite can be found in the original article. ** = The AUC value was> 0.90 for each of the metabolites individually, the study did not present an analysis of the combined.
| Metabolites | Studies | Sample | Disturbance | Statistical analysis |
|---|---|---|---|---|
| Alanine | Abdula et al. 2020 | Cervical tissue | Increase | - |
| Silva et al. 2008 | Cervical tissue | Decrease | P=0.01 | |
| Sitter et al. 2004 | Cervical tissue | Increase | - | |
| Chen et al. 2021 | Cervical tissue | Increase | P=0.003 | |
| Ye et al. 2015 | Plasma/Serum | Increase | P=0.024 | |
| Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 | |
| Creatine | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Silva et al. 2008 | Cervical tissue | Decrease | P= 0.008 | |
| Sitter et al. 2004 | Cervical tissue | Increase | - | |
| Hasim et al. 2012 | Plasma/Serum | Decrease | P>0.05 | |
| Lactate | Abdula et al. 2020 | Cervical tissue | Increase | - |
| Sitter et al. 2004 | Cervical tissue | - | - | |
| Chen et al. 2021 | Cervical tissue | Increase | P=0.01 | |
| Khan et al. 2019 | Plasma/Serum | Increase | AUC= 0.74 / P<0.001 | |
| Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 | |
| β-glucose | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Sitter et al. 2004 | Cervical tissue | Decrease | - | |
| Ye et al. 2015 | Plasma/Serum | Decrease | P=0.039 | |
| Hasim et al. 2012 | Plasma/Serum | Increase | P>0.05 | |
| Valine | Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.000 | |
| Shi et al. 2015 | Plasma/Serum | Decrease | P=0.001 | |
| Tyrosine | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Chen et al. 2021 | Cervical tissue | Increase | P=0.009 | |
| Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 | |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.027 | |
| Isoleucine | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 | |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.004 | |
| PC | Silva et al. 2008 | Cervical tissue | Increase | P>0.05 |
| Nan et al. 2021 | Plasma/Serum | Decrease | P<0.001 | |
| Cheng et al. 2020 | Plasma/Serum | - | AUC: 0.842 | |
| Zhou et al. 2019 | Plasma/Serum | Increase GP group Decrease PP group | P=0.00 / AT×PR -AUC:0.78 / AT×PB -AUC:0.78 / PB × PR - AUC:0.90 | |
| Yin et al. 2015 | Plasma/Serum | Decrease | AUC>0.79 | |
| Acetate | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Ye et al. 2015 | Plasma/Serum | Increase | P<0.05 | |
| Hasim et al. 2012 | Plasma/Serum | Increase | P<0.05 | |
| α-glucose | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Hasim et al. 2012 | Plasma/Serum | Increase | P>0.05 | |
| Aspartate | Chen et al. 2021 | Cervical tissue | Increase | P<0.001 |
| Khan et al. 2019 | Plasma/Serum | Increase | AUC= 0.76 / P<0.001 | |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.000 | |
| Glutamate | Khan et al. 2019 | Plasma/Serum | Increase | AUC= 0.81 / P<0.001 |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.007 | |
| Lyso PC | Yang et al. 2017 | Plasma/Serum | Increase | AUC: 0.94 |
| Yin et al. 2015 | Plasma/Serum | Increase | AUC>80 | |
| Threonine | Yang et al. 2017 | Plasma/Serum | Increase | AUC: 0.85 |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.007 | |
| Glutamine | Ye et al. 2015 | Plasma/Serum | Decrease | P=0.030 |
| Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 | |
| Formate | Ye et al. 2015 | Plasma/Serum | Decrease | P=0.012 |
| Hasim et al. 2012 | Plasma/Serum | Increase | P<0.05 | |
| Choline | Silva et al. 2008 | Cervical tissue | Increase | P>0.05 |
| Sitter et al. 2004 | Cervical tissue | Increase | - | |
| Phenylalanine | Abdula et al. 2020 | Cervical tissue | Decrease | - |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.002 | |
| Histidine | Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.000 | |
| Phosphate | Silva et al. 2008 | Cervical tissue | Increase | P=0.004 |
| Chen et al. 2021 | Cervical tissue | Increase | P=0.017 | |
| Shi et al. 2015 | Plasma/Serum | Increase | P=0.02 | |
| Taurine | Sitter et al. 2004 | Cervical tissue | Increase | - |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.047 | |
| Leucine | Hasim et al. 2012 | Plasma/Serum | Decrease | P<0.05 |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.003 | |
| Glycine | Chen et al. 2021 | Cervical tissue | Increase | P=0.001 |
| Hasim et al. 2013 | Plasma/Serum | Decrease | P=0.000 | |
| PE | Nan et al. 2021 | Plasma/Serum | Decrease | P<0.05 |
| Cheng et al. 2020 | Plasma/Serum | - | AUC>0.788 |
Caption: BT = before treatment / GP = good prognosis / PP = poor prognosis. / AUC = Area under the curve. / LysoPC = lysophosphatidylcholine. - = not reported
In 10 studies that used blood serum/plasma as a biological sample, 18 metabolites were found in common. Metabolites showing decrease in patients with CC were: valine, glutamine, histidine, isoleucine and leucine. In two articles lysophosphatidylcholines (lysoPC) and acetate were described as increased. B-glucose, alanine, lactate, aspartate, glutamate, formate, tyrosine and threonine were not consistentaly altered in the presented studies. Phosphatidylcholine was decreased in the three studies where it was detected, interestingly Zhou et al. in 2019 reported that this reduction occurred among patients with poor prognosis, whereas patients with good prognosis had an increase in this metabolite in their samples (Table 4).
Nine of the reviewed articles performed statistical analysis on the accuracy of metabolimic techniques used in the diagnosis of CC (
Only Zhou et al. (2019), used metabolomics as a prognostic analysis method in cervical cancer. This study, which analyzed blood plasma samples, demonstrated that phosphatidylcholine [PC (15: 0/16: 0)], phosphatidylglycerol [PG (12: 0/13: 0), lactosylceramide [LacCer (d18: 1/16: 0 )], D-Maltose and phthalic acid can function as potential biomarkers when analyzed together to monitor the prognosis of patients with CC (
Eleven studies analyzed patients with cervical intraepithelial lesions. Abdula et al. (2019) found that the levels of α-glucose and β-glucose were reduced in the tissue of patients with CIN when compared with patients with CC (
The age of patients with cervical cancer ranged between 40 and 50 years in the studies listed by this systematic review (
The main metabolites described as relevant by the articles studied in this review are amino acids and components related to carbohydrate metabolism (
The decrease in amino acid levels in samples from patients with CC may be related to an increased demand for these metabolites by cancer cells, which need them for survival and growth
Figure 1 Connection between the metabolic pathways of the most cited compounds among the selected studies.
Legend: Metabolites in orange were cited as relevant by three or more articles, the metabolites in green were cited by at least two studies. Metabolites with (*) had a consistent disturbance in all articles in which they were mentioned. Metabolic pathway references extracted from Kanehisa (1996).
The decrease of this component in the plasma may be directly related to the activation of oncogenes and the inactivation of tumor suppressors, such as the Rb protein, which induce the use of glutamine and other important metabolites during the unregulated proliferation of neoplastic cells.
The most prominent altered metabolites within carbohydrate metabolism were β-glucose, α-glucose and lactate. β-glucose levels were decreased in most articles that reported it, in contrast, there was no consensus for α-glucose. Lactate was reported to be increased in three of the four studies that described lactate alteration (
Glucose depletion and lactate increase maybe due to the Warburg effect, which suggests that an anaerobic glycolysis process can occur in tumors where glucose is converted into lactic acid even in the presence of oxygen
Other metabolites such as phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine and choline were found to be significantly increased in the reviewed studies (
The diagnostic capacity of metabolomics was tested by nine studies in this review. Sensitivity was greater than 90%, specificity ranged from 73% to 99% and AUC varied from 0.78 to 0.99 for sets of metabolites. These results demonstrate that metabolomic approaches can be an accurate method for the diagnosis of cervical cancer. Ilhan et al. (2019), Khan et al. (2019), Hasim et al. (2012), Chen et al. (2021) and Cheng et al. (2020) also highlighted the ability of metabolomics to differentiate cancer patients from those with CIN (
The analysis carried out using QUADOMICS (
The reviewed CC metabolomic studies suggest blood as the main type of biological sample used and mass spectrometry as the preferred analytical platform. The average age of patients with cervical cancer ranged between 40-50 years and most studies added a comparative group of patients with cervical intraepithelial lesions to perform their analysis. Furthermore, we can conclude that the methodological quality of the identified articles was heterogeneous, with a gap of 8 QUADOMICS criteria being met between the studies with the highest scores compared to the lowest scores.
The main metabolites found to be associated with cervical cancer were alanine, creatine, valine, tyrosine, isoleucine, phosphatidylcholine, acetate, lactate and β-glucose. This suggest that a metabolomic profile associated with changes in energy pathways and their connections with amino acid depletion, as well as with changes in the metabolism of glycerophospholipids may be common to CC. In addition, the results described point to the effectiveness of metabolomics in the diagnosis of cervical cancer and in the differentiation of patients with intraepithelial lesions. The expansion and refinement of metabolomic approaches towards CC hold great potential for clinical applications.
| DATA BASE | SEARCH STRATEGY |
|---|---|
| PUBMED | “metabolome”[MeSH Terms] OR “metabolome”[All Fields] OR “metabolomes”[All Fields] OR “metabolomics”[MeSH Terms] OR “metabolomics”[All Fields] OR “metabolomic”[All Fields] AND “uterine cervical neoplasms”[MeSH Terms] OR (“uterine”[All Fields] AND “cervical”[All Fields] AND “neoplasms”[All Fields]) OR “uterine cervical neoplasms”[All Fields] OR (“cervical”[All Fields] AND “cancer”[All Fields]) OR “cervical cancer”[All Fields] OR (“cancer”[All Fields] AND “cervix”[All Fields]) OR “cancer of cervix”[All Fields] OR (“cervix”[All Fields] AND “neoplasms”[All Fields]) OR “cervix neoplasms”[All Fields] OR (“uterine”[All Fields] AND “cervix”[All Fields]) OR “uterine cervix”[All Fields] |
| LILACS, SCIELO AND BVS | (metabolomics cervical cancer) OR (metabolomics cancer of cervix) OR (metabolomics cervix neoplasms) OR (metabolomics uterine cervical neoplasms) OR (metabolomics of the uterine cervix) OR (metabolomics uterine cervix neoplasms) |
| GOOGLE SCHOLAR AND OPEN GRAY | Metabolomics cervical cancer Metabolomics cancer of cervix Metabolomics cervix neoplasms Metabolomics uterine cervical neoplasms Metabolomics of the uterine cervix Metabolomics uterine cervix neoplasms |
Figure S1 Flowchart of study selection.
Figure S2 General characteristics of the selected studies. A. Country of origin and number of studies. B. Analytical platforms used in CC metabolomic studies. C. biological sample type / analytical platform on CC metabolomics studies. Caption: MS = Mass spectrometry. NMR = Nuclear magnetic resonance. LA-REIMS = Laser ablation coupled with rapid evaporative mass spectrometry. LC-MS = Liquid chromatography coupled to mass spectrometry. GC-MS = Gas chromatography coupled to mass spectrometry. VOCs = Volatile organic compounds
| ITEM | Abdula et al. 2020 | Rodrígues-Esquivel et al. 2018 | Ilhan et al. 2019 | Khan et al. 2019 | Paraskevaidi et al. 2020 | Yang et al. 2017 | Ye et al. 2015 | Zhou et al. 2019 | Silva et al. 2008 | Hasim et al. 2012 | Hasim et al. 2013 | Shi et al. 2015 | Sitter et al. 2004 | Yin et al. 2015 | Chen et al. 2021 | Nan et al. 2021 | Cheng et al. 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 3 | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 4.1 | N | Y | Y | Y | Y | Y | N | Y | N | Y | Y | N | N | Y | N | Y | Y |
| 4.2 | N | Y | Y | Y | Y | Y | N | Y | N | N | Y | N | Y | Y | N | Y | Y |
| 5 | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | Y |
| 6 | ? | ? | ? | ? | Y | Y | Y | Y | Y | Y | Y | ? | Y | Y | ? | Y | Y |
| 7 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 8 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 9 | ? | Y | Y | ? | Y | Y | ? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 10 | N | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y |
| 11 | N | Y | N | Y | Y | N | N | N | Y | N | N | N | Y | Y | N | N | N |
| 12 | ? | Y | N | ? | Y | N | N | N | N | N | N | N | N | N | N | N | N |
| 13 | Y | Y | Y | Y | ? | Y | Y | Y | ? | Y | Y | Y | Y | Y | Y | Y | Y |
| 14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 15 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 16 | N | N | N | N | Y | Y | N | Y | N | N | N | N | N | Y | N | N | Y |
| TOTAL | 5 | 12 | 10 | 10 | 13 | 12 | 7 | 12 | 8 | 10 | 11 | 8 | 10 | 13 | 8 | 11 | 12 |
Legend: Y = criteria met / N = criteria not met / ? = Unclear, N / A = not applicable
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Journal: Brazilian Journal of Oncology
DOI: 10.1055/s-00059887
e-issn: 2526-8732
Publisher: Thieme Revinter Publicações Ltda.
Publisher address: Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
No citations found for this article.
1. [Access in: 09/02/2020]. Available in: [online]. Available from: <https://cutt.ly/ihjmtKW>.
2. Instituto Nacional de Câncer (Brasil). Estimativa 2020. Incidência do Câncer no Brasil. INCA, 2020.
3. [Access in: 09/02/2020]. Available in: [online]. Available from: <https://mortalidade.inca.gov.br/MortalidadeWeb/>.
4. Serrano, B and Brotons, M and Bosch, FX and Bruni, L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol [Internet] [online]. 2018, vol. 47, p. 14-26.
5. Petry, KU. HPV and cervical cancer. Scand J Clin Lab Invest Suppl. [Internet] [online]. 2014, vol. 244, p. 59-62.
6. Li, B and He, X and Jia, W and Li, H. Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review. Molecules. [Internet] [online]. 2017, vol. 22, p. 1-10.
7. Kumar, A and Misra, BB. Challenges and Opportunities in Cancer Metabolomics. Proteomics. [Internet] [online]. 2019, vol. 19, p. 21-22.
8. Galvão, TF and Pansani, TSA and Harrad, D. Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiol e Serviços Saúde. [Internet] [online]. 2015, vol. 24, p. 335-342.
9. Lumbreras, B and Porta, M and Márquez, S and Pollán, M and Parker, LA and Hernández-Aguado, I. QUADOMICS: An adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of '-omics'-based technologies. Clin Biochem [Internet] [online]. 2008, vol. 41, p. 1316-1325.
10. Whiting, P and Rutjes, A. W and Reitsma, J. B and Bossuyt, P. M and Kleijnen, J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC medical research methodology. [Internet] [online]. 2003, vol. 3, p. 25-25.
11. Abudula, A and Rouzi, N and Xu, L and Yang, Y and Hasimu, A. Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection. Bosnian journal of basic medical sciences. [Internet] [online]. 2020, vol. 20, p. 78-87.
12. Rodríguez-Esquivel, M and Rosales, J and Castro, R and Apresa-García, T and Garay, Ó and Romero-Morelos, P and Marrero-Rodríguez, D and Taniguchi-Ponciano, K and López-Romero, R and Guerrero-Flores, H and Morales, B and Mendoza-Rodríguez, M and Mosso-Lara, D and Núñez-Nolasco, I and Castro-Alba, P and Meza-Toledo, S. E and Salcedo, M. Volatolome of the Female Genitourinary Area: Toward the Metabolome of Cervical Cancer. Archives of medical research. [Internet] [online]. 2018, vol. 49, p. 27-35.
13. Ilhan, Z. E and Łaniewski, P and Thomas, N and Roe, D. J and Chase, D. M and Herbst-Kralovetz, M. M. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. [Internet] [online]. 2019, vol. 44, p. 675-690.
14. Khan, I and Nam, M and Kwon, M and Seo, S. S and Jung, S and Han, J. S and Hwang, G. S and Kim, M. K. LC/MS-Based Polar Metabolite Profiling Identified Unique Biomarker Signatures for Cervical Cancer and Cervical Intraepithelial Neoplasia Using Global and Targeted Metabolomics. Cancers. [Internet] [online]. 2019, vol. 11, p. 511-511.
15. Paraskevaidi, M and Cameron, S and Whelan, E and Bowden, S and Tzafetas, M and Mitra, A and Semertzidou, A and Athanasiou, A and Bennett, P. R and MacIntyre, D. A and Takats, Z and Kyrgiou, M. Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening. EBioMedicine [Internet] [online]. 2020, vol. 60, p. 103017-103017.
16. Yang, K and Xia, B and Wang, W and Cheng, J and Yin, M and Xie, H and Li, J and Ma, L and Yang, C and Li, A and Fan, X and Dhillon, H. S and Hou, Y and Lou, G and Li, K. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. Scientific reports. [Internet] [online]. 2017, vol. 7, p. 43353-43353.
17. Ye, N and Liu, C and Shi, P. Metabolomics analysis of cervical cancer, cervical intraepithelial neoplasia and chronic cervicitis by 1H NMR spectroscopy. European journal of gynaecological oncology. [Internet] [online]. 2015, vol. 36, p. 174-180.
18. Zhou, H and Li, Q and Wang, T and Liang, H and Wang, Y and Duan, Y and Song, M and Wang, Y and Jin, H. Prognostic biomarkers of cervical squamous cell carcinoma identified via plasma metabolomics. Medicine. [Internet] [online]. 2019, vol. 98, p. e16192.
19. De Silva, S. S and Payne, G. S and Thomas, V and Carter, P. G and Ind, T. E and deSouza, N. M. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31) P magic angle spinning MRS of intact tissue. NMR in biomedicine. [Internet] [online]. 2009, vol. 22, p. 1316-1325.
20. Hasim, A and Ali, M and Mamtimin, B and Ma, J. Q and Li, Q. Z and Abudula, A. Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by (1) H NMR spectroscopy. Experimental and therapeutic medicine. [Internet] [online]. 2012, vol. 3, p. 945-951.
21. Hasim, A and Aili, A and Maimaiti, A and Mamtimin, B and Abudula, A and Upur, H. Plasma-free amino acid profiling of cervical cancer and cervical intraepithelial neoplasia patients and its application for early detection. Molecular biology reports. [Internet] [online]. 2013, vol. 40, p. 5853-5859.
22. Shi, P and Zhang, L and Ye, N. Serum Metabolomic Analysis of Cervical Cancer Patients by Gas Chromatography-Mass Spectrometry. Asian J. Chem. [Internet] [online]. 2015, vol. 27, p. 547-551.
23. Sitter, B and Bathen, T and Hagen, B and Arentz, C and Skjeldestad, F. E and Gribbestad, I. S. Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. Magma (New York, N.Y.). [Internet] [online]. 2004, vol. 16, p. 174-181.
24. Yin, M. Z and Tan, S and Li, X and Hou, Y and Cao, G and Li, K and Kou, J and Lou, G. (2016). Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. [Internet] [online]. , vol. 37, p. 5485-5492.
25. Chen, X and Yi, C and Yang, M. J and Sun, X and Liu, X and Ma, H and Li, Y and Li, H and Wang, C and He, Y and Chen, G and Chen, S and Yu, L and Yu, D. (2021). Metabolomics study reveals the potential evidence of metabolic reprogramming towards the Warburg effect in precancerous lesions. Journal of Cancer [online]. , vol. 12, p. 1563-1574.
26. Nam, M and Seo, S. S and Jung, S and Jang, S. Y and Lee, J and Kwon, M and Khan, I and Ryu, D. H and Kim, M. K and Hwang, G. S. (2021). Comparable Plasma Lipid Changes in Patients with High-Grade Cervical Intraepithelial Neoplasia and Patients with Cervical Cancer. Journal of proteome research [online]. , vol. 20, p. 740-750.
27. Cheng, F and Wen, Z and Feng, X and Wang, X and Chen, Y. (2020). A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer. Life sciences [online]. , vol. 260, p. 118489-118489.
28. Fontham, ETH and Wolf, AMD and Church, TR. Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society. CA Cancer J Clin. [Internet] [online]. 2020. https://doi.org/10.3322/caac.21628 Ver referência
29. Ahmed-Salim, Y and Galazis, N and Bracewell-Milnes, T and Phelps, D. L and Jones, B. P and Chan, M and Munoz-Gonzales, M. D and Matsuzono, T and Smith, J. R and Yazbek, J and Krell, J and Ghaem-Maghami, S and Saso, S. The application of metabolomics in ovarian cancer management: a systematic review. International journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyAdvance online publication. [Internet] [online]. 2020. https://doi.org/10.1136/ijgc-2020-001862 Ver referência
30. Li, Z and Zhang, H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cellular and molecular life sciences: CMLS, [Internet] [online]. 2016, vol. 73, p. 377-392.
31. Turkoglu, O and Zeb, A and Graham, S and Szyperski, T and Szender, J. B and Odunsi, K and Bahado-Singh, R. Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. Metabolomics: Official journal of the Metabolomic Society. [Internet] [online]. 2016, vol. 12, p. 60-60.
32. Kanehisa, M. Toward pathway engineering: a new database of genetic and molecular pathways. Science & Technology Japan, [Internet] [online]. 1996, p. 34-38.
33. Liberti, M. V and Locasale, J. W. The Warburg Effect: How Does it Benefit Cancer Cells?. Trends in biochemical sciences. [Internet] [online]. 2016, vol. 41, p. 211-218.
34. Hsu, P. P and Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell, [Internet] [online]. 2008, vol. 134, p. 703-707.
35. Vazquez, A and Liu, J and Zhou, Y and Oltvai, Z. N. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC systems biology, [Internet] [online]. 2010, vol. 4, p. 58-58.
36. Pascale, R. M and Calvisi, D. F and Simile, M. M and Feo, C. F and Feo, F. The Warburg Effect 97 Years after Its Discovery. Cancers. [Internet] [online]. 2020, vol. 12, p. 2819-2819.
37. Wang, H and Tso, V. K and Slupsky, C. M and Fedorak, R. N. Metabolomics and detection of colorectal cancer in humans: a systematic review. Future oncology (London, England). [Internet] [online]. 2010, vol. 6, p. 1395-1406.
38. Glunde, K and Penet, M. F and Jiang, L and Jacobs, M. A and Bhujwalla, Z. M. Choline metabolism-based molecular diagnosis of cancer: an update. Expert review of molecular diagnostics. [Internet] [online]. 2015, vol. 15, p. 735-747.
39. Ridgway, N. D. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Critical reviews in biochemistry and molecular biology. [Internet] [online]. 2013, vol. 48, p. 20-38.
40. Rižner, T. L. Discovery of biomarkers for endometrial cancer: current status and prospects. Expert review of molecular diagnostics. [Internet] [online]. 2016, vol. 16, p. 1315-1336.
Dados de acesso insuficientes para visualização no mapa.